Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127693 | 0.80 | CYP2D6 (0.82) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6127516 | 0.80 | CYP2D6 (0.82) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1164461 | 0.79 | CYP2D6 (0.74) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10690110 | 0.79 | TSHR (0.89) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23052533 | 0.78 | CYP2D6 (0.72) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9286827 | 0.77 | CYP2D6 (0.66) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28820376 | 0.77 | USP2 (0.67) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7193591 | 0.77 | CYP2D6 (0.70) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL27601052 | 0.77 | CYP2D6 (0.70) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6122455 | 0.76 | TSHR (0.70) | TSHRALDH1A1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | TSHR 1779/4885ALDH1A1 3496/4885CYP2D6 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.